LCM MRD™ (capillary ctDNA)

Highlights:

• TimepointDx LCM™ MRD detects small fragments of circulating tumor DNA (ctDNA) within capillary blood samples for treatment efficacy, monitoring of disease progression, and post-therapeutic long-term monitoring of recurrence.
• Close, longitudinal timepoints via LCM™ MRD enables robust monitoring by using ctDNA as the specific biomarker of interest for early detection and active surveillance strategies.
• TimepointDx LCM™ MRD enables matching of patients to effective targeted treatments and personalized medicine strategies at earlier interventional stages due to the ease of collection and ctDNA analysis via LCM™.
• By focusing exclusively on ctDNA, enhanced coverage and reads for capillary ctDNA is achieved by novel isolation of ctDNA within capillary samples followed by WGS, WES, or WTS, with preferential coverage and read allocation for known oncogenes of interest (similar to TSO500 panel).
• TimepointDx LCM™ MRD enables tumor microenvironment molecular characterization by using capillary samples as a proxy over multiple timepoints.
• TimepointDx LCM™ MRD can measure neoadjuvant therapy response, overall MRD and burden, monitor adjuvant therapy response over time, and monitor ctDNA levels for recurrence.
• TimepointDx LCM™ MRD provides quantitative capillary ctDNA parts per million (PPM) scores in addition to adjacent transcriptomics and proteomics data as ad-hoc supplementary data. The capillary ctDNA is devoid of genomic DNA, whereby the ctDNA is further sequences (WGS and/or WES).
• TimepointDx LCM™ MRD can achieve ctDNA detection between ~130-180 days in advance of radiographic data (in development).

See White Paper for Details.